地特胰岛素的研究进展  

Research Progress of Insulin Detemir

作　　者：罗惠辛[1] 宋淑萍[1] 

机构地区：[1]天津市天和医院内分泌科,天津300050

出　　处：《医学综述》2012年第4期600-603,共4页Medical Recapitulate

摘　　要：地特胰岛素是基础胰岛素类似物,有其独特的分子结构,可与血浆白蛋白可逆性结合,具有长且相对平缓的时间作用曲线,可以显著减少受试者个体内变异性,作用持续时间与甘精胰岛素没有任何差异。众多的临床试验及观察显示地特胰岛素可明显降低糖化血红蛋白、空腹血糖(FPG)、FPG变异性,与甘精胰岛素和中性鱼精蛋白锌胰岛素无明显差异。但在减少低血糖发生和体质量控制方面显示出其优越性。地特胰岛素与胰岛素样生长因子1受体亲和力低,很多研究证实其和人胰岛素相比促生长效应没有变化,但是胰岛素类似物长期应用的安全性尚有争议。Insulin detemir is one of basal human insulin analogues.It has unique molecule structure,with an acylated fatty acid chain that enables reversible binding to albumin.It has longer and relative flat time action curve,can decrease individual variability significantly,and its duration of action is similar with insulin glargine.Many clinical studies have showed insulin detemir reduced glycosylated hemoglobin,fasting plasma glucose（FPG）and FPG variability obviously compared with insulin glargine and neutral protamin hagedorn.It showed its advantage in hypoglycaemia event rate and weight gain.Insulin detemir has low affinity with insulin-like growth factor-1 receptor,and is proved,by many studies,no increased or decreased growth promoting effect compared to human insulin,though the safety of long-term insulin analogues treatment is still controversial.

关 键 词：糖尿病 地特胰岛素 有效性 安全性 肿瘤风险 

分 类 号：R587.1[医药卫生—内分泌]